Cargando…
Effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in Estonia
OBJECTIVE: Reaching a genetic diagnosis of mitochondrial disorders (MDs) is challenging due to their broad phenotypic and genotypic heterogeneity. However, there is growing evidence that the use of whole exome sequencing (WES) for diagnosing patients with a clinical suspicion of an MD is effective (...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043467/ https://www.ncbi.nlm.nih.gov/pubmed/30009132 http://dx.doi.org/10.1016/j.ymgmr.2018.03.004 |
_version_ | 1783339288342036480 |
---|---|
author | Puusepp, Sanna Reinson, Karit Pajusalu, Sander Murumets, Ülle Õiglane-Shlik, Eve Rein, Reet Talvik, Inga Rodenburg, Richard J. Õunap, Katrin |
author_facet | Puusepp, Sanna Reinson, Karit Pajusalu, Sander Murumets, Ülle Õiglane-Shlik, Eve Rein, Reet Talvik, Inga Rodenburg, Richard J. Õunap, Katrin |
author_sort | Puusepp, Sanna |
collection | PubMed |
description | OBJECTIVE: Reaching a genetic diagnosis of mitochondrial disorders (MDs) is challenging due to their broad phenotypic and genotypic heterogeneity. However, there is growing evidence that the use of whole exome sequencing (WES) for diagnosing patients with a clinical suspicion of an MD is effective (39–60%). We aimed to study the effectiveness of WES in clinical practice in Estonia, in patients with an unsolved, but suspected MD. We also show our first results of mtDNA analysis obtained from standard WES reads. METHODS: Retrospective cases were selected from a database of 181 patients whose fibroblast cell cultures had been stored from 2003 to 2013. Prospective cases were selected during the period of 2014–2016 from patients referred to a clinical geneticist in whom an MD was suspected. We scored each patient according to the mitochondrial disease criteria (MDC) (Morava et al., 2006) after re-evaluation of their clinical data, and then performed WES analysis. RESULTS: A total of 28 patients were selected to the study group. A disease-causing variant was found in 16 patients (57%) using WES. An MD was diagnosed in four patients (14%), with variants in the SLC25A4, POLG, SPATA5, and NDUFB11 genes. Other variants found were associated with a neuromuscular disease (SMN1, MYH2, and LMNA genes), neurodegenerative disorder (TSPOAP1, CACNA1A, ALS2, and SCN2A genes), multisystemic disease (EPG5, NKX1–2, ATRX, and ABCC6 genes), and one in an isolated cardiomyopathy causing gene (MYBPC3). The mtDNA point mutation was found in the MT-ATP6 gene of one patient upon mtDNA analysis. CONCLUSIONS: The diagnostic yield of WES in our cohort was 57%, proving to be a very good effectiveness. However, MDs were found in only 14% of the patients. We suggest WES analysis as a first-tier method in clinical genetic practice for children with any multisystem, neurological, and/or neuromuscular problem, as nuclear DNA variants are more common in children with MDs; a large number of patients harbor disease-causing variants in genes other than the mitochondria-related ones, and the clinical presentation might not always point towards an MD. We have also successfully conducted analysis of mtDNA from standard WES reads, providing further evidence that this method could be routinely used in the future. |
format | Online Article Text |
id | pubmed-6043467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-60434672018-07-13 Effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in Estonia Puusepp, Sanna Reinson, Karit Pajusalu, Sander Murumets, Ülle Õiglane-Shlik, Eve Rein, Reet Talvik, Inga Rodenburg, Richard J. Õunap, Katrin Mol Genet Metab Rep Research Paper OBJECTIVE: Reaching a genetic diagnosis of mitochondrial disorders (MDs) is challenging due to their broad phenotypic and genotypic heterogeneity. However, there is growing evidence that the use of whole exome sequencing (WES) for diagnosing patients with a clinical suspicion of an MD is effective (39–60%). We aimed to study the effectiveness of WES in clinical practice in Estonia, in patients with an unsolved, but suspected MD. We also show our first results of mtDNA analysis obtained from standard WES reads. METHODS: Retrospective cases were selected from a database of 181 patients whose fibroblast cell cultures had been stored from 2003 to 2013. Prospective cases were selected during the period of 2014–2016 from patients referred to a clinical geneticist in whom an MD was suspected. We scored each patient according to the mitochondrial disease criteria (MDC) (Morava et al., 2006) after re-evaluation of their clinical data, and then performed WES analysis. RESULTS: A total of 28 patients were selected to the study group. A disease-causing variant was found in 16 patients (57%) using WES. An MD was diagnosed in four patients (14%), with variants in the SLC25A4, POLG, SPATA5, and NDUFB11 genes. Other variants found were associated with a neuromuscular disease (SMN1, MYH2, and LMNA genes), neurodegenerative disorder (TSPOAP1, CACNA1A, ALS2, and SCN2A genes), multisystemic disease (EPG5, NKX1–2, ATRX, and ABCC6 genes), and one in an isolated cardiomyopathy causing gene (MYBPC3). The mtDNA point mutation was found in the MT-ATP6 gene of one patient upon mtDNA analysis. CONCLUSIONS: The diagnostic yield of WES in our cohort was 57%, proving to be a very good effectiveness. However, MDs were found in only 14% of the patients. We suggest WES analysis as a first-tier method in clinical genetic practice for children with any multisystem, neurological, and/or neuromuscular problem, as nuclear DNA variants are more common in children with MDs; a large number of patients harbor disease-causing variants in genes other than the mitochondria-related ones, and the clinical presentation might not always point towards an MD. We have also successfully conducted analysis of mtDNA from standard WES reads, providing further evidence that this method could be routinely used in the future. Elsevier 2018-03-15 /pmc/articles/PMC6043467/ /pubmed/30009132 http://dx.doi.org/10.1016/j.ymgmr.2018.03.004 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Puusepp, Sanna Reinson, Karit Pajusalu, Sander Murumets, Ülle Õiglane-Shlik, Eve Rein, Reet Talvik, Inga Rodenburg, Richard J. Õunap, Katrin Effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in Estonia |
title | Effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in Estonia |
title_full | Effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in Estonia |
title_fullStr | Effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in Estonia |
title_full_unstemmed | Effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in Estonia |
title_short | Effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in Estonia |
title_sort | effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in estonia |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043467/ https://www.ncbi.nlm.nih.gov/pubmed/30009132 http://dx.doi.org/10.1016/j.ymgmr.2018.03.004 |
work_keys_str_mv | AT puuseppsanna effectivenessofwholeexomesequencinginunsolvedpatientswithaclinicalsuspicionofamitochondrialdisorderinestonia AT reinsonkarit effectivenessofwholeexomesequencinginunsolvedpatientswithaclinicalsuspicionofamitochondrialdisorderinestonia AT pajusalusander effectivenessofwholeexomesequencinginunsolvedpatientswithaclinicalsuspicionofamitochondrialdisorderinestonia AT murumetsulle effectivenessofwholeexomesequencinginunsolvedpatientswithaclinicalsuspicionofamitochondrialdisorderinestonia AT oiglaneshlikeve effectivenessofwholeexomesequencinginunsolvedpatientswithaclinicalsuspicionofamitochondrialdisorderinestonia AT reinreet effectivenessofwholeexomesequencinginunsolvedpatientswithaclinicalsuspicionofamitochondrialdisorderinestonia AT talvikinga effectivenessofwholeexomesequencinginunsolvedpatientswithaclinicalsuspicionofamitochondrialdisorderinestonia AT rodenburgrichardj effectivenessofwholeexomesequencinginunsolvedpatientswithaclinicalsuspicionofamitochondrialdisorderinestonia AT ounapkatrin effectivenessofwholeexomesequencinginunsolvedpatientswithaclinicalsuspicionofamitochondrialdisorderinestonia |